ZeroStack Corp’s Revenue Decline and Crypto Treasury Volatility Challenge Growth Prospects
ZeroStack's business model combines pharmaceutical distribution through its subsidiary Phatebo with a cryptocurrency treasury centered on the 0G Token, resulting in significant revenue contraction and substantial operating losses in 2025.
ZeroStack Corp operates at the intersection of AI infrastructure investment via its 0G Token holdings and global pharmaceutical distribution through Phatebo. Despite an established pharma segment, total revenues declined by 40% in 2025 amid operational pressures and impairments from digital asset valuations. This dual business exposes ZeroStack to earnings volatility driven by cryptocurrency price swings, culminating in large operating losses and negative cash flow. Future growth depends on AI infrastructure adoption and regulatory developments, but remains constrained by ongoing losses and capital needs.
Historical Financial Performance Summary: FY2022-FY2025
Historical performance (annual)
| FY | Rev ($mm) | Net ($mm) | CFO ($mm) | OpInc ($mm) | Rev YoY | Net YoY |
|---|---|---|---|---|---|---|
| 2025 | 36 | -9 | -155 | -40.0% | ||
| 2024 | 60 | -16 | -5 | -16 | -21.8% | +72.1% |
| 2023 | 76 | -57 | -8 | -50 | +104.7% | -8.4% |
| 2022 | 37 | -53 | -16 | -53 |
Source: SEC companyfacts cache [F1].
Capital returns and efficiency (annual)
| FY | Buybacks ($) | FCF ($mm) | ROE% |
|---|---|---|---|
| 2025 | -9 | ||
| 2024 | -5 | -352.7 | |
| 2023 | 0 | -9 | -890.6 |
| 2022 | 255000 | -17 | -92.6 |
Source: SEC companyfacts cache [F1].
Revenue Trends Amidst Pharmaceutical Distribution and Crypto Volatility
ZeroStack's consolidated revenue declined markedly from $76.1 million in FY2023 to $35.7 million in FY2025—a drop of nearly 40% year-over-year from FY2024—reflecting pressures across its diversified operations [F1]. The pharmaceutical distribution arm Phatebo contributes steady revenues across multiple regions including Europe (28 countries), Asia, Latin America, and North America but has been unable to offset the overall top-line contraction [S1][S13].
Phatebo focuses on wholesale distribution of pharmaceuticals for various health indications such as oncology therapies and neurological disorders [S1]. However, this segment faces typical industry challenges including competitive pricing pressures, regulatory scrutiny over import/export tariffs and trade policies, as well as logistical risks that impact margins and sales growth potential [S10][S13]. Payment terms ranging up to six months add complexity to revenue recognition timing [S10].
Cryptocurrency Treasury Strategy Impacting Financials
Central to ZeroStack’s growth strategy is its investment in AI infrastructure through strategic ownership of the proprietary digital asset known as the 0G Token which fuels its decentralized AI network [S1]. In fiscal year 2025, the company completed several private placements including a May offering raising approximately $1.1 million and a September PIPE Offering which generated gross proceeds exceeding $13 million—partly settled via issuance of over 70 million tokens valued at approximately $54.7 million at issuance date [S1][S2].
While these capital raises have funded digital asset acquisitions integral to ZeroStack’s vision, accounting for these holdings under prevailing standards requires marking them to fair value each reporting period with unrealized gains or losses flowing through income statements [S1][F1]. Consequently, significant impairments tied to declines or volatility in token prices contributed heavily to the sharp increase in operating losses recorded in FY2025.
Risk disclosures highlight vulnerabilities including price volatility driven by speculative trading activity; technological risks relating to blockchain security upgrades; competition from government-backed or alternative digital currencies; evolving regulatory landscapes potentially constraining token usage or legality; as well as operational risks tied to custodianship and trading platform stability [S7][S8][S12].
Liquidity Position and Capital Structure
As of December 31, 2025, ZeroStack held cash and equivalents near $5.6 million alongside current assets totaling approximately $8.7 million against nearly equivalent current liabilities of $8.6 million yielding a current ratio around 1.01—signaling tight liquidity conditions necessitating careful working capital management [F1][S4].
The Phatebo subsidiary maintains credit facilities totaling €2.4 million ($2.7 million USD) secured by guarantees with variable interest ranging from about 5% to over 10%, which represent notable short-term debt service obligations impacting cash flows [S5].
Funding has been sourced primarily through equity offerings supporting crypto acquisitions alongside borrowings at the subsidiary level; however ongoing operating losses underscore the need for future capital raises that may dilute shareholders further [S4][S14][N1].
Cash Flow Dynamics and Capital Allocation
Operating cash flow was negative $8.7 million for FY2025 while capital expenditures remained modest at roughly $127 thousand indicating limited reinvestment amid persistent cash burn from operations compounded by non-cash impairment charges related to digital assets [F1]. Free cash flow remains negative reflecting challenges funding organic growth or strategic investments internally.
The company has not engaged in share repurchases nor declared dividends recently consistent with conserving cash amid continued losses and strategic expansion efforts centered on AI infrastructure development.
Risks and Forward Outlook
Key risks include:
- High volatility of cryptocurrency holdings directly impacting earnings;
- Regulatory uncertainty surrounding digital asset legality and compliance requirements;
- Litigation exposure linked to crypto activities consuming management focus;
- Integration complexities from acquisitions potentially diluting operational effectiveness;
- Dependencies on technical blockchain upgrades affecting token utility;
- Reliance on third-party custodians/trading venues vulnerable to financial distress;
- Political and geopolitical factors influencing pharmaceutical distribution channels [S7][S8][S29].[F1]
Management emphasizes ambitions toward expanding decentralized AI infrastructure powered by the open-source 0G Network but acknowledges that near-term results will depend heavily on market acceptance of their technology platform alongside evolving legal frameworks governing digital assets [N1][S1].
Conclusion
ZeroStack Corp embodies a hybrid business model balancing established pharmaceutical distribution with pioneering but volatile cryptocurrency treasury investments underpinning an AI infrastructure vision. The company faces acute challenges reflected in declining revenues driven by pharma sector pressures combined with outsized impairment-driven operating losses stemming from crypto asset volatility.
Liquidity constraints coupled with ongoing net losses present capital allocation dilemmas requiring further financing rounds that may dilute existing shareholders but are essential for sustaining operations and pursuing strategic growth opportunities within emerging blockchain-enabled AI markets.
Disclaimer: This analysis is based solely on publicly available financial data and SEC filings as of early 2026 and does not constitute investment advice.
Disclaimer: This is research-only, informational analysis and not investment advice. It may include AI-generated interpretation and general industry context. Always verify important details using primary sources.
Comments